What is GLOBUS MEDICAL INC's earnings per share (EPS)?

GLOBUS MEDICAL INC (GMED) reported diluted earnings per share of $3.92 for fiscal year 2025. This represents a 422.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

GLOBUS MEDICAL (GMED) Financials

GMED NYSE

Trailing 12 months to June 30, 2026

Revenue $3.1B +19.7% YoY

Net Income $535.4M +50.1% YoY

EPS (Diluted) $3.90 +50.0% YoY

Free Cash Flow $755.6M +43.3% YoY

Market Cap $11.0B as of Oct 26, 2026

Price / Sales 3.5x on $3.1B revenue, trailing 12 months to June 30, 2026

Price / Earnings 20.5x on $535.4M net income, trailing 12 months to June 30, 2026

Price / Book 2.3x on $4.8B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GMED SEC filings page.

GLOBUS MEDICAL INC (GMED) reported $3.1B in revenue over the twelve months to Jun 30, 2026, up 19.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GMED FY2025 2026-10-25

FY2025 shows a business emerging from a balance-sheet step-up with sharply better margins, cash conversion, and lower liabilities.

The FY2025 rebound was not simply sales-driven: revenue rose 16.7% while cost of revenue fell 7.5%, lifting gross margin by 8.5 percentage points. Operating income then rose 189.1% even as SG&A increased 20.1%, pointing to a major shift in cost absorption or revenue mix rather than volume alone.

Cash conversion strengthened materially: operating cash flow reached $753M against net income of $538M, so reported earnings were accompanied by more cash than profit. After $165M of capital expenditures, free cash flow was $589M, showing reinvestment did not absorb the year's cash generation.

The FY2023 balance-sheet expansion was unusually large, with assets rising 145.0% and goodwill increasing 626.5%. By FY2025, liabilities had fallen 32.1% while equity rose 9.5%; the current ratio also recovered to 4.3x from 2.5x in FY2024, indicating a less debt-heavy and less compressed short-term funding structure.

Financial Health Signals

Financial Health Score 77/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of GLOBUS MEDICAL INC's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

GLOBUS MEDICAL INC has an operating margin of 16.3%, meaning the company retains $16 of operating profit per $100 of revenue. This strong profitability earns a score of 66/100, reflecting efficient cost management and pricing power. This is up from 6.6% the prior year.

Growth

GLOBUS MEDICAL INC's revenue surged 16.7% year-over-year to $2.9B, reflecting rapid business expansion. This strong growth earns a score of 92/100.

Leverage

Liquidity

With a current ratio of 4.26, GLOBUS MEDICAL INC holds $4.26 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 88/100.

Cash Flow

GLOBUS MEDICAL INC converts 20.0% of revenue into free cash flow ($588.8M). This strong cash generation earns a score of 81/100.

Returns

GLOBUS MEDICAL INC's ROE of 11.8% shows moderate profitability relative to equity, earning a score of 54/100. This is up from 2.5% the prior year.

Altman Z-Score Safe

10.62

GLOBUS MEDICAL INC scores 10.62, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $11.0B against total liabilities of $729.5M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

8/8

GLOBUS MEDICAL INC passes 8 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.40x

For every $1 of reported earnings, GLOBUS MEDICAL INC generates $1.40 in operating cash flow ($753.4M OCF vs $537.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$789.6M

YoY+5.9%

QoQ+3.9%

5Y CAGR+25.8%

10Y CAGR+19.1%

GLOBUS MEDICAL INC generated $789.6M in revenue in Q2 2026. This represents an increase of 5.9% from the same quarter a year earlier. Against the prior quarter it is up 3.9%.

EBITDA

$252.6M

YoY+72.1%

QoQ+14.7%

5Y CAGR+31.2%

GLOBUS MEDICAL INC's EBITDA was $252.6M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 72.1% from the same quarter a year earlier. Against the prior quarter it is up 14.7%.

Net Income

$151.6M

YoY-25.3%

QoQ+21.9%

5Y CAGR+29.5%

10Y CAGR+19.4%

GLOBUS MEDICAL INC reported $151.6M in net income in Q2 2026. This represents a decrease of 25.3% from the same quarter a year earlier. Against the prior quarter it is up 21.9%.

EPS (Diluted)

$1.10

YoY-26.2%

QoQ+22.2%

GLOBUS MEDICAL INC earned $1.10 per diluted share (EPS) in Q2 2026. This represents a decrease of 26.2% from the same quarter a year earlier. Against the prior quarter it is up 22.2%.

Cash & Balance Sheet

Free Cash Flow

$176.6M

YoY+464.1%

QoQ+8.5%

5Y CAGR+28.3%

10Y CAGR+30.3%

GLOBUS MEDICAL INC generated $176.6M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 464.1% from the same quarter a year earlier. Against the prior quarter it is up 8.5%.

Cash & Debt

$507.7M

YoY+121.3%

QoQ-9.5%

5Y CAGR+13.6%

10Y CAGR+18.2%

GLOBUS MEDICAL INC held $507.7M in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding

134M

YoY-0.6%

QoQ-1.1%

GLOBUS MEDICAL INC had 134M shares outstanding in Q2 2026. This represents a decrease of 0.6% from the same quarter a year earlier. Against the prior quarter it is down 1.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

69.4%

YoY+2.8pp

QoQ+0.2pp

5Y change-5.1pp

10Y change-6.8pp

GLOBUS MEDICAL INC's gross margin was 69.4% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.

Operating Margin

23.1%

YoY+12.9pp

QoQ+3.3pp

5Y change+4.8pp

GLOBUS MEDICAL INC's operating margin was 23.1% in Q2 2026, reflecting core business profitability. This is up 12.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.3 percentage points.

Net Margin

19.2%

YoY-8.0pp

QoQ+2.8pp

5Y change+2.6pp

10Y change+0.4pp

GLOBUS MEDICAL INC's net profit margin was 19.2% in Q2 2026, showing the share of revenue converted to profit. This is down 8.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.8 percentage points.

Return on Equity

3.2%

YoY-1.5pp

QoQ+0.6pp

5Y change+0.7pp

10Y change-0.1pp

GLOBUS MEDICAL INC's quarterly ROE was 3.2% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 1.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.

Capital Allocation

R&D Spending

$36.3M

YoY-9.1%

QoQ-0.5%

5Y CAGR+18.5%

GLOBUS MEDICAL INC invested $36.3M in research and development in Q2 2026. This represents a decrease of 9.1% from the same quarter a year earlier. Against the prior quarter it is down 0.5%.

Share Buybacks

$136.1M

YoY+444.2%

QoQn/m

GLOBUS MEDICAL INC spent $136.1M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 444.2% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Capital Expenditures

$33.2M

YoY-28.8%

QoQ-16.3%

5Y CAGR+31.7%

10Y CAGR+11.9%

GLOBUS MEDICAL INC invested $33.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 28.8% from the same quarter a year earlier. Against the prior quarter it is down 16.3%.

GMED Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GMED quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$3.1B	$2.9B+16.7%	$2.5B+60.6%	$1.6B+53.3%	$1.0B+6.8%	$958.1M+21.4%	$789.0M+0.5%	$785.4M+10.2%	$713.0M+12.1%	$636.0M+12.8%	$564.0M+3.5%	$544.8M+14.8%	$474.4M+9.2%	$434.5M+12.6%	$386.0M+16.4%	$331.5M
Cost of Revenue	$989.1M	$957.8M-7.5%	$1.0B+88.9%	$548.2M+107.9%	$263.7M+10.2%	$239.2M+10.0%	$217.5M+20.8%	$180.0M+12.9%	$159.4M+6.0%	$150.5M+11.7%	$134.7M+1.8%	$132.3M+19.5%	$110.8M+10.4%	$100.3M+33.4%	$75.2M+9.3%	$68.8M
Gross Profit	$2.2B	$2.0B+33.5%	$1.5B+45.4%	$1.0B+34.4%	$759.1M+5.6%	$718.9M+25.8%	$571.6M-5.6%	$605.4M+9.4%	$553.6M+14.0%	$485.5M+13.1%	$429.3M+4.1%	$412.4M+13.4%	$363.6M+8.8%	$334.1M+7.5%	$310.8M+18.3%	$262.7M
R&D Expenses	$147.1M	$147.2M-10.1%	$163.8M+32.0%	$124.0M+69.8%	$73.0M-25.0%	$97.3M+15.2%	$84.5M+40.7%	$60.1M+8.2%	$55.5M+27.1%	$43.7M-1.9%	$44.5M+22.6%	$36.3M+16.5%	$31.2M+16.0%	$26.9M-3.8%	$27.9M+19.0%	$23.5M
SG&A Expenses	$1.2B	$1.2B+20.1%	$981.4M+52.4%	$643.8M+49.0%	$432.1M+5.9%	$408.1M+15.1%	$354.8M0.0%	$354.8M+13.9%	$311.6M+16.3%	$267.8M+20.6%	$222.2M+5.7%	$210.2M+11.5%	$188.6M+3.3%	$182.5M+8.1%	$168.9M+20.3%	$140.4M
Operating Income	$639.5M	$479.8M+189.1%	$166.0M+24.7%	$133.1M-41.6%	$228.0M+32.6%	$172.0M+54.3%	$111.4M-35.2%	$172.0M+1.6%	$169.3M+4.6%	$161.8M+5.0%	$154.1M-10.5%	$172.2M+24.5%	$138.4M+36.1%	$101.7M-11.4%	$114.8M+17.9%	$97.4M
EBITDA	N/A	$756.7M+80.4%	$419.4M+50.5%	$278.7M-5.9%	$296.2M+22.5%	$241.8M+38.7%	$174.3M-22.4%	$224.7M+6.5%	$211.0M+3.5%	$203.9M+5.7%	$192.9M-1.7%	$196.3M+22.6%	$160.1M+32.3%	$121.1M-8.9%	$132.9M+16.3%	$114.3M
Interest Expense	N/A	N/A	$4.2M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$124.7M	$67.2M+278.8%	$17.7M-58.3%	$42.5M-19.5%	$52.9M+69.3%	$31.2M+32.2%	$23.6M-32.0%	$34.7M+8.1%	$32.1M-48.7%	$62.6M+18.2%	$52.9M-11.8%	$60.0M+30.0%	$46.2M+38.2%	$33.4M-18.2%	$40.8M+12.9%	$36.2M
Net Income	$535.4M	$537.9M+422.3%	$103.0M-16.2%	$122.9M-35.4%	$190.2M+27.5%	$149.2M+45.9%	$102.3M-34.1%	$155.2M-0.8%	$156.5M+45.8%	$107.3M+2.9%	$104.3M-7.5%	$112.8M+21.9%	$92.5M+34.8%	$68.6M-7.1%	$73.8M+21.5%	$60.8M
EPS (Basic)	N/A	$3.98+423.7%	$0.76-30.3%	$1.09-42.3%	$1.89+27.7%	$1.48+42.3%	$1.04-33.8%	$1.57-1.9%	$1.60+42.9%	$1.12+2.8%	$1.09-8.4%	$1.19+21.4%	$0.98+32.4%	$0.74-9.8%	$0.82+18.8%	$0.69
EPS (Diluted)	$3.90	$3.92+422.7%	$0.75-29.9%	$1.07-42.2%	$1.85+28.5%	$1.44+42.6%	$1.01-33.6%	$1.52-1.3%	$1.54+40.0%	$1.10+1.9%	$1.08-7.7%	$1.17+20.6%	$0.97+32.9%	$0.73-8.8%	$0.80+19.4%	$0.67
Diluted Shares (Avg)	N/A	137M-0.6%	138M+20.3%	115M+11.7%	103M-0.9%	104M+2.6%	101M-1.0%	102M+0.7%	101M+3.5%	98M+1.5%	96M+0.4%	96M+0.6%	95M+1.3%	94M+2.2%	92M+2.0%	90M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$789.6M+5.9%	$759.9M+27.0%	$826.4M+25.7%	$769.0M+22.9%	$745.3M+18.4%	$598.1M-1.4%	$657.3M+6.6%	$625.7M+63.1%
Cost of Revenue	$241.4M-2.9%	$234.1M+19.8%	$261.1M-0.9%	$252.5M-6.6%	$248.8M-4.3%	$195.4M-19.1%	$263.4M-0.8%	$270.5M+99.8%
Gross Profit	$548.2M+10.4%	$525.8M+30.6%	$565.3M+43.5%	$516.5M+45.4%	$496.6M+34.3%	$402.7M+10.3%	$393.9M+12.2%	$355.2M+43.1%
R&D Expenses	$36.3M-9.1%	$36.5M+10.4%	$36.2M+8.2%	$38.1M+7.6%	$40.0M+6.0%	$33.1M-42.3%	$33.4M-36.1%	$35.4M+20.6%
SG&A Expenses	$286.8M-5.5%	$297.8M+22.6%	$318.5M+25.8%	$313.6M+30.6%	$303.6M+26.8%	$242.8M-2.4%	$253.2M+3.3%	$240.1M+53.7%
Operating Income	$182.4M+139.7%	$150.4M+55.0%	$169.3M+181.0%	$137.4M+185.6%	$76.1M+53.4%	$97.0M+1113.0%	$60.3M+495.4%	$48.1M+11805.4%
EBITDA	$252.6M+72.1%	$220.2M+35.4%	$238.7M+87.2%	$208.6M+81.0%	$146.8M+29.5%	$162.7M+157.1%	$127.5M+55.5%	$115.2M+204.2%
Income Tax	$38.2Mn/m	$32.8M+16.2%	$28.6Mn/m	$25.0M+381.7%	-$14.7M-192.7%	$28.2Mn/m	-$1.8M-118.5%	$5.2M+238.1%
Net Income	$151.6M-25.3%	$124.3M+64.7%	$140.6M+430.4%	$119.0M+129.5%	$202.8M+538.7%	$75.5Mn/m	$26.5M+76.3%	$51.8M+5094.0%
EPS (Basic)	$1.12-25.3%	$0.92+67.3%	$1.05+425.0%	$0.88+131.6%	$1.50+552.2%	$0.55n/m	$0.20+233.3%	$0.38+3700.0%
EPS (Diluted)	$1.10-26.2%	$0.90+66.7%	$1.02+436.8%	$0.88+131.6%	$1.49+547.8%	$0.54n/m	$0.19+111.1%	$0.38+3700.0%
Diluted Shares (Avg)	137M+0.6%	138M-1.1%	N/A	135M-1.9%	136M-0.4%	140M+3.3%	N/A	138M+19.8%

Not reported in any period shown, so not listed: Interest Expense.

GMED Balance Sheet

GMED quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$5.3B+1.0%	$5.3B+3.3%	$5.1B+145.0%	$2.1B+6.1%	$2.0B+16.5%	$1.7B+9.6%	$1.5B+17.8%	$1.3B+20.6%	$1.1B+16.3%	$927.6M+11.2%	$834.1M+18.6%	$703.5M+24.2%	$566.3M+26.7%	$447.1M+35.7%	$329.4M
Current Assets	$2.1B-2.4%	$2.2B+13.7%	$1.9B+94.8%	$983.3M+13.7%	$864.5M+5.2%	$821.8M+19.5%	$687.5M+9.0%	$630.7M+1.7%	$620.3M+20.7%	$513.8M-5.7%	$544.8M+15.9%	$470.0M+12.8%	$416.8M+15.7%	$360.1M+39.2%	$258.8M
Cash & Equivalents	$526.2M-32.9%	$784.4M+67.9%	$467.3M+210.6%	$150.5M-22.1%	$193.1M-19.4%	$239.4M+22.5%	$195.5M+40.0%	$139.6M+17.5%	$118.8M+77.5%	$67.0M+16.1%	$57.7M-29.9%	$82.3M-8.6%	$90.0M-57.6%	$212.4M+48.9%	$142.7M
Short-Term Investments	$31.1M-70.6%	$105.6M+109.2%	$50.5M-82.9%	$295.6M+18.1%	$250.4M+33.6%	$187.3M+61.8%	$115.8M-42.1%	$199.9M-21.6%	$254.9M+14.1%	$223.4M+1.1%	$220.9M+50.8%	$146.4M-1.7%	$149.0Mn/m	$0n/m	$0
Inventory	$759.3M+15.2%	$659.2M-22.3%	$848.1M+183.7%	$299.0M+26.2%	$237.0M+3.4%	$229.2M+16.7%	$196.3M+49.6%	$131.3M+21.1%	$108.4M-3.8%	$112.7M+7.1%	$105.3M+15.7%	$90.9M+29.3%	$70.3M+12.9%	$62.3M+31.5%	$47.4M
Accounts Receivable	$678.9M+21.7%	$557.7M+10.8%	$503.2M+136.0%	$213.2M+29.7%	$164.4M+16.1%	$141.7M-8.2%	$154.3M+12.6%	$137.1M+17.5%	$116.7M+26.8%	$92.0M+18.4%	$77.7M+3.0%	$75.4M+20.9%	$62.4M+16.7%	$53.5M+14.5%	$46.7M
Long-Term Investments	$71.8M+8.6%	$66.1M-12.3%	$75.4M-84.8%	$495.9M-11.8%	$562.5M+56.9%	$358.5M-12.5%	$409.5M+55.6%	$263.1M+368.7%	$56.1M-7.1%	$60.4M+24.0%	$48.8M-35.3%	$75.3M+106.3%	$36.5Mn/m	$0n/m	$0
Goodwill	$1.4B+0.2%	$1.4B-0.2%	$1.4B+626.5%	$197.5M+9.9%	$179.7M+14.7%	$156.7M+21.7%	$128.8M+4.1%	$123.7M-0.1%	$123.9M+17.0%	$105.9M+15.2%	$92.0M+72.9%	$53.2M+189.5%	$18.4M+19.5%	$15.4M+56.7%	$9.8M
Total Liabilities	$729.5M-32.1%	$1.1B-1.3%	$1.1B+373.6%	$229.8M+6.4%	$215.9M+24.6%	$173.2M+33.6%	$129.6M+12.6%	$115.2M+4.0%	$110.7M+15.9%	$95.6M-19.5%	$118.8M+0.6%	$118.1M+25.7%	$93.9M+54.9%	$60.6M+29.2%	$46.9M
Current Liabilities	$498.5M-41.8%	$855.9M+118.2%	$392.3M+146.4%	$159.2M+13.6%	$140.2M+16.0%	$120.8M+8.4%	$111.4M+15.9%	$96.1M+3.3%	$93.1M+16.5%	$79.9M-3.4%	$82.7M-7.5%	$89.4M+31.6%	$67.9M+72.0%	$39.5M+35.0%	$29.3M
Non-Current Liabilities	$231.0M+5.7%	$218.5M-68.6%	$695.8M+886.2%	$70.5M-6.8%	$75.7M+44.5%	$52.4M+187.5%	$18.2M-4.3%	$19.0M+7.8%	$17.7M+12.7%	$15.7M-56.6%	$36.1M+25.8%	$28.7M+10.3%	$26.0M+23.1%	$21.1M+19.7%	$17.6M
Long-Term Debt	N/A	N/A	$417.4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$4.6B+9.5%	$4.2B+4.5%	$4.0B+116.5%	$1.8B+6.0%	$1.7B+15.6%	$1.5B+7.4%	$1.4B+18.3%	$1.2B+22.5%	$967.8M+16.3%	$832.1M+16.3%	$715.3M+22.2%	$585.5M+23.9%	$472.4M+22.2%	$386.5M+36.8%	$282.5M
Retained Earnings	$1.4B+20.4%	$1.2B+1.4%	$1.1B-8.3%	$1.2B+3.8%	$1.2B+14.3%	$1.0B-0.3%	$1.0B+17.4%	$892.7M+21.3%	$736.2M+17.1%	$628.9M+19.9%	$524.6M+27.4%	$411.8M+29.0%	$319.3M+27.4%	$250.7M+41.7%	$176.8M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$5.5B+10.6%	$5.4B+15.5%	$5.3B+1.0%	$5.1B+0.2%	$5.0B-0.7%	$4.7B-4.7%	$5.3B+3.3%	$5.1B-5.0%
Current Assets	$2.2B+28.1%	$2.2B+28.5%	$2.1B-2.4%	$1.9B-6.4%	$1.7B-10.1%	$1.7B-6.5%	$2.2B+13.7%	$2.1B+7.3%
Cash & Equivalents	$507.7M+121.3%	$561.0M+21.6%	$526.2M-32.9%	$371.8M-40.3%	$229.4M-44.1%	$461.3M+30.3%	$784.4M+67.9%	$622.8M+122.7%
Short-Term Investments	$87.4Mn/m	$68.9Mn/m	$31.1M-70.6%	$18.8M-73.9%	$0-100.0%	$0-100.0%	$105.6M+109.2%	$71.9M-62.0%
Inventory	$810.9M+5.0%	$772.6M+16.4%	$759.3M+15.2%	$771.5M+7.5%	$772.1M+0.2%	$663.6M-18.7%	$659.2M-22.3%	$717.7M-20.7%
Accounts Receivable	$692.2M+13.2%	$686.4M+28.3%	$678.9M+21.7%	$619.1M+5.3%	$611.6M0.0%	$535.1M+0.1%	$557.7M+10.8%	$588.0M+19.0%
Long-Term Investments	$245.4Mn/m	$169.4Mn/m	$71.8M+8.6%	$16.7M+35.7%	$0-100.0%	$0-100.0%	$66.1M-12.3%	$12.3M-95.5%
Goodwill	$1.4B+0.2%	$1.4B+0.4%	$1.4B+0.2%	$1.4B+0.2%	$1.4B-1.3%	$1.4B-1.3%	$1.4B-0.2%	$1.4B+27.6%
Total Liabilities	$719.7M+8.2%	$707.2M+13.5%	$729.5M-32.1%	$696.8M-31.5%	$665.4M-34.6%	$623.1M-39.0%	$1.1B-1.3%	$1.0B-13.0%
Current Liabilities	$479.3M+12.9%	$482.5M+25.4%	$498.5M-41.8%	$466.0M-43.0%	$424.7M-46.5%	$384.7M-51.1%	$855.9M+118.2%	$818.1M+90.8%
Non-Current Liabilities	$240.3M-0.2%	$224.8M-5.7%	$231.0M+5.7%	$230.9M+16.3%	$240.7M+7.8%	$238.4M+1.5%	$218.5M-68.6%	$198.6M-73.2%
Total Equity	$4.8B+11.0%	$4.7B+15.8%	$4.6B+9.5%	$4.4B+8.1%	$4.3B+8.0%	$4.1B+4.2%	$4.2B+4.5%	$4.1B-2.8%
Retained Earnings	$1.5B+25.8%	$1.5B+45.9%	$1.4B+20.4%	$1.3B+14.8%	$1.2B+13.0%	$1.0B-1.0%	$1.2B+1.4%	$1.1B-16.4%

Not reported in any period shown, so not listed: Long-Term Debt.

GMED Cash Flow Statement

GMED quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$910.4M	$753.4M+44.7%	$520.6M+113.8%	$243.5M+36.4%	$178.5M-35.4%	$276.3M+39.0%	$198.8M+15.6%	$172.0M-5.3%	$181.6M+14.2%	$159.1M+7.6%	$147.8M+19.2%	$124.0M+56.6%	$79.2M-15.3%	$93.5M+22.2%	$76.5M+0.1%	$76.4M
Depreciation & Amortization	N/A	$276.8M+9.3%	$253.4M+74.1%	$145.5M+113.2%	$68.3M-2.3%	$69.9M+11.1%	$62.9M+19.2%	$52.7M+26.7%	$41.6M-1.0%	$42.1M+8.5%	$38.8M+61.0%	$24.1M+10.7%	$21.8M+12.2%	$19.4M+7.1%	$18.1M+6.8%	$16.9M
Stock-Based Compensation	N/A	$49.8M-8.1%	$54.2M+2.7%	$52.7M+60.7%	$32.8M+7.3%	$30.6M+13.0%	$27.1M+3.8%	$26.1M+19.1%	$21.9M+49.1%	$14.7M+29.0%	$11.4M+18.1%	$9.6M+35.6%	$7.1M+37.4%	$5.2M+11.7%	$4.6M+41.1%	$3.3M
Capital Expenditures	$154.8M	$164.7M+42.7%	$115.4M+47.5%	$78.3M+5.7%	$74.0M+30.1%	$56.9M-10.6%	$63.7M-10.0%	$70.8M+18.5%	$59.7M+16.4%	$51.3M+25.4%	$40.9M-19.4%	$50.8M+105.1%	$24.8M+4.5%	$23.7M-4.1%	$24.7M+9.8%	$22.5M
Free Cash Flow	$755.6M	$588.8M+45.3%	$405.2M+145.2%	$165.2M+58.2%	$104.4M-52.4%	$219.4M+62.3%	$135.1M+33.5%	$101.2M-17.0%	$121.9M+13.2%	$107.8M+0.8%	$106.9M+46.0%	$73.2M+34.6%	$54.4M-22.0%	$69.8M+34.6%	$51.8M-3.9%	$53.9M
Investing Cash Flow	-$499.0M	-$355.0Mn/m	-$176.1M-158.1%	$303.0Mn/m	-$110.4Mn/m	-$375.9Mn/m	-$117.3Mn/m	-$140.3Mn/m	-$193.0Mn/m	-$111.3Mn/m	-$162.7Mn/m	-$153.1Mn/m	-$100.0Mn/m	-$227.2Mn/m	-$30.7Mn/m	-$30.0M
Financing Cash Flow	-$135.1M	-$679.2Mn/m	-$27.7Mn/m	-$231.8Mn/m	-$110.0M-303.1%	$54.1Mn/m	-$38.7M-258.2%	$24.4M-25.0%	$32.6M+1903.1%	$1.6M+246.0%	$470K-89.0%	$4.3M-67.0%	$12.9M+17.6%	$11.0M-54.2%	$24.0Mn/m	-$14.7M
Share Buybacks	$221.1M	$300.5M+250.2%	$85.8M-62.0%	$225.6M+56.1%	$144.5M	N/A	$104.7M	N/A	N/A	N/A	N/A	N/A	N/A	$0n/m	$0-100.0%	$10.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$209.7M+169.4%	$202.4M+14.1%	$248.6M+18.2%	$249.7M+22.6%	$77.9M+43.5%	$177.3M+238.4%	$210.3M+100.9%	$203.7M+303.4%
Depreciation & Amortization	$70.2M-0.7%	$69.9M+6.4%	$69.0M+2.1%	$71.2M+6.1%	$70.7M+10.9%	$65.7M+18.8%	$67.6M-6.1%	$67.1M+79.2%
Stock-Based Compensation	$13.4M-1.7%	$12.6M-4.5%	N/A	$11.5M-5.5%	$13.6M+6.3%	$13.2M-23.5%	N/A	$12.2M+23.6%
Capital Expenditures	$33.2M-28.8%	$39.6M+9.7%	$46.2M+170.0%	$35.8M-14.6%	$46.6M+67.5%	$36.1M+26.4%	$17.1M-25.2%	$42.0M+94.8%
Free Cash Flow	$176.6M+464.1%	$162.7M+15.3%	$202.4M+4.7%	$213.9M+32.3%	$31.3M+18.3%	$141.2M+492.8%	$193.2M+136.2%	$161.7M+458.6%
Investing Cash Flow	-$129.0Mn/m	-$182.7M-239.0%	-$111.4Mn/m	-$75.8Mn/m	-$299.1Mn/m	$131.4Mn/m	-$104.1M-132.5%	-$15.0Mn/m
Financing Cash Flow	-$134.5Mn/m	$18.2Mn/m	$13.2M-77.9%	-$32.0M-263.6%	-$24.9M-386.3%	-$635.4Mn/m	$59.7Mn/m	$19.6M+1274.2%
Share Buybacks	$136.1M+444.2%	$0-100.0%	$45.0M+4400.0%	$40.0Mn/m	$25.0M+1599.5%	$190.5M+128.6%	$1.0M	$0

Not reported in any period shown, so not listed: Dividends Paid.

GMED Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GMED quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	67.4%+8.5pp	58.9%-6.2pp	65.0%-9.2pp	74.2%-0.8pp	75.0%+2.6pp	72.4%-4.6pp	77.1%-0.6pp	77.6%+1.3pp	76.3%+0.2pp	76.1%+0.4pp	75.7%-0.9pp	76.6%-0.3pp	76.9%-3.6pp	80.5%+1.3pp	79.3%
Operating Margin	16.3%+9.7pp	6.6%-1.9pp	8.5%-13.8pp	22.3%+4.3pp	17.9%+3.8pp	14.1%-7.8pp	21.9%-1.8pp	23.8%-1.7pp	25.4%-1.9pp	27.3%-4.3pp	31.6%+2.4pp	29.2%+5.8pp	23.4%-6.3pp	29.7%+0.4pp	29.4%
Net Margin	18.3%+14.2pp	4.1%-3.7pp	7.8%-10.8pp	18.6%+3.0pp	15.6%+2.6pp	13.0%-6.8pp	19.8%-2.2pp	21.9%+5.1pp	16.9%-1.6pp	18.5%-2.2pp	20.7%+1.2pp	19.5%+3.7pp	15.8%-3.3pp	19.1%+0.8pp	18.3%
Return on Equity	11.8%+9.3pp	2.5%-0.6pp	3.1%-7.2pp	10.3%+1.7pp	8.6%+1.8pp	6.8%-4.3pp	11.1%-2.1pp	13.2%+2.1pp	11.1%-1.5pp	12.5%-3.2pp	15.8%0.0pp	15.8%+1.3pp	14.5%-4.6pp	19.1%-2.4pp	21.5%
Return on Assets	10.1%+8.2pp	2.0%-0.5pp	2.4%-6.7pp	9.2%+1.5pp	7.6%+1.5pp	6.1%-4.0pp	10.1%-1.9pp	12.0%+2.1pp	10.0%-1.3pp	11.3%-2.3pp	13.5%+0.4pp	13.2%+1.0pp	12.1%-4.4pp	16.5%-1.9pp	18.4%
Current Ratio	4.26+1.7x	2.54-2.3x	4.88-1.3x	6.180.0x	6.17-0.6x	6.80+0.6x	6.17-0.4x	6.56-0.1x	6.67+0.2x	6.43-0.2x	6.59+1.3x	5.26-0.9x	6.13-3.0x	9.11+0.3x	8.84
Debt-to-Equity	N/A	N/A	0.10	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Liabilities-to-Equity	0.16-0.1x	0.260.0x	0.27+0.1x	0.120.0x	0.120.0x	0.120.0x	0.090.0x	0.100.0x	0.110.0x	0.11-0.1x	0.170.0x	0.200.0x	0.200.0x	0.160.0x	0.17
Asset Turnover	0.55+0.1x	0.48+0.2x	0.31-0.2x	0.490.0x	0.490.0x	0.470.0x	0.510.0x	0.550.0x	0.590.0x	0.610.0x	0.650.0x	0.67-0.1x	0.77-0.1x	0.86-0.1x	1.01
FCF Margin	20.0%+4.0pp	16.1%+5.5pp	10.5%+0.3pp	10.2%-12.7pp	22.9%+5.8pp	17.1%+4.2pp	12.9%-4.2pp	17.1%+0.2pp	16.9%-2.0pp	19.0%+5.5pp	13.5%+2.0pp	11.5%-4.6pp	16.1%+2.6pp	13.4%-2.8pp	16.3%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	69.4%+2.8pp	69.2%+1.9pp	68.4%+8.5pp	67.2%+10.4pp	66.6%+7.9pp	67.3%+7.1pp	59.9%+3.0pp	56.8%-7.9pp
Operating Margin	23.1%+12.9pp	19.8%+3.6pp	20.5%+11.3pp	17.9%+10.2pp	10.2%+2.3pp	16.2%+14.9pp	9.2%+7.5pp	7.7%+7.6pp
Net Margin	19.2%-8.0pp	16.4%+3.7pp	17.0%+13.0pp	15.5%+7.2pp	27.2%+22.2pp	12.6%+13.8pp	4.0%+1.6pp	8.3%+8.0pp
Return on Equity	3.2%-1.5pp	2.6%+0.8pp	3.1%+2.4pp	2.7%+1.4pp	4.7%+3.9pp	1.8%+2.0pp	0.6%+0.3pp	1.3%+1.3pp
Return on Assets	2.8%-1.3pp	2.3%+0.7pp	2.6%+2.1pp	2.3%+1.3pp	4.1%+3.4pp	1.6%+1.7pp	0.5%+0.2pp	1.0%+1.0pp
Current Ratio	4.62+0.5x	4.56+0.1x	4.26+1.7x	4.13+1.6x	4.07+1.7x	4.45+2.1x	2.54-2.3x	2.51-2.0x
Liabilities-to-Equity	0.150.0x	0.150.0x	0.16-0.1x	0.16-0.1x	0.15-0.1x	0.15-0.1x	0.260.0x	0.250.0x
Asset Turnover	0.140.0x	0.140.0x	0.160.0x	0.150.0x	0.150.0x	0.130.0x	0.130.0x	0.12+0.1x
FCF Margin	22.4%+18.2pp	21.4%-2.2pp	24.5%-4.9pp	27.8%+2.0pp	4.2%0.0pp	23.6%+19.7pp	29.4%+16.1pp	25.8%+18.3pp

Not reported in any period shown, so not listed: Debt-to-Equity.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
GLOBUS MEDICAL INC GMED	FY2025	$2.9B	$537.9M	18.3%	$11.0B	77/100
Bio-Rad Laboratories, Inc. BIO	FY2025	$2.6B	$759.9M	29.4%	$10.0B	51/100
iRhythm Holdings, Inc. IRTC	FY2025	$747.1M	-$44.6M	-6.0%	$4.0B	44/100
Glaukos Corporation GKOS	FY2025	$507.4M	-$187.7M	-37.0%	$10.5B	51/100
Bruker Corporation BRKR	FY2025	$3.4B	-$8.6M	-0.3%	$8.9B	43/100

Where GLOBUS MEDICAL INC Ranks

Frequently Asked Questions

What is GLOBUS MEDICAL INC's annual revenue?

GLOBUS MEDICAL INC (GMED) reported $2.9B in total revenue for fiscal year 2025. This represents a 16.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is GLOBUS MEDICAL INC's revenue growing?

GLOBUS MEDICAL INC (GMED) revenue grew by 16.7% year-over-year, from $2.5B to $2.9B in fiscal year 2025.

Is GLOBUS MEDICAL INC profitable?

Yes, GLOBUS MEDICAL INC (GMED) reported a net income of $535.4M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net income of $537.9M, with a net profit margin of 18.3%.

What is GLOBUS MEDICAL INC's EBITDA?

GLOBUS MEDICAL INC (GMED) had EBITDA of $756.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is GLOBUS MEDICAL INC's gross margin?

GLOBUS MEDICAL INC (GMED) had a gross margin of 67.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is GLOBUS MEDICAL INC's operating margin?

GLOBUS MEDICAL INC (GMED) had an operating margin of 16.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is GLOBUS MEDICAL INC's net profit margin?

GLOBUS MEDICAL INC (GMED) had a net profit margin of 18.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is GLOBUS MEDICAL INC's return on equity (ROE)?

GLOBUS MEDICAL INC (GMED) has a return on equity of 11.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is GLOBUS MEDICAL INC's free cash flow?

GLOBUS MEDICAL INC (GMED) generated $588.8M in free cash flow during fiscal year 2025. This represents a 45.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is GLOBUS MEDICAL INC's operating cash flow?

GLOBUS MEDICAL INC (GMED) generated $753.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are GLOBUS MEDICAL INC's total assets?

GLOBUS MEDICAL INC (GMED) had $5.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are GLOBUS MEDICAL INC's capital expenditures?

GLOBUS MEDICAL INC (GMED) invested $164.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does GLOBUS MEDICAL INC spend on research and development?

GLOBUS MEDICAL INC (GMED) invested $147.2M in research and development during fiscal year 2025.

Does GLOBUS MEDICAL INC buy back shares?

Yes, GLOBUS MEDICAL INC (GMED) spent $300.5M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does GLOBUS MEDICAL INC have outstanding?

GLOBUS MEDICAL INC (GMED) had 135M shares outstanding as of fiscal year 2025.

What is GLOBUS MEDICAL INC's current ratio?

GLOBUS MEDICAL INC (GMED) had a current ratio of 4.26 as of fiscal year 2025, which is generally considered healthy.

What is GLOBUS MEDICAL INC's liabilities-to-equity ratio?

GLOBUS MEDICAL INC (GMED) had a liabilities-to-equity ratio of 0.16 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

What is GLOBUS MEDICAL INC's return on assets (ROA)?

GLOBUS MEDICAL INC (GMED) had a return on assets of 10.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is GLOBUS MEDICAL INC's P/E ratio?

GLOBUS MEDICAL INC (GMED) trades at 20.5x earnings, its market capitalization divided by $535.4M net income, trailing 12 months to June 30, 2026. The market capitalization is $11.0B as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is GLOBUS MEDICAL INC's price-to-sales ratio?

GLOBUS MEDICAL INC (GMED) trades at 3.5x sales, its market capitalization divided by $3.1B revenue, trailing 12 months to June 30, 2026. The market capitalization is $11.0B as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is GLOBUS MEDICAL INC's Altman Z-Score?

GLOBUS MEDICAL INC (GMED) has an Altman Z-Score of 10.62, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is GLOBUS MEDICAL INC's Piotroski F-Score?

GLOBUS MEDICAL INC (GMED) has a Piotroski F-Score of 8 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are GLOBUS MEDICAL INC's earnings high quality?

GLOBUS MEDICAL INC (GMED) has an earnings quality ratio of 1.40x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is GLOBUS MEDICAL INC?

GLOBUS MEDICAL INC (GMED) scores 77 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.